Page last updated: 2024-12-11
golotimod
Description
golotimod: a synthetic dipeptide that stimulates immune system activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (41)
| Synonym |
|---|
| 229305-39-9 |
| (2r)-2-amino-5-[[(1s)-2-hydroxy-1-(1h-indol-3-ylmethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid |
| (gamma-glutamyl-l-tryptophan) |
| golotimod |
| gamma-d-glu-l-trp |
| scv 07 |
| scv07 |
| scv-07 |
| D08928 |
| golotimod (usan/inn) |
| golotimod [usan:inn] |
| 637c487y09 , |
| l-tryptophan, d-gamma-glutamyl- |
| gamma-d-glutamyl-l-tryptophan |
| (2r)-2-amino-5-(((1s)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid |
| unii-637c487y09 |
| CHEMBL2103812 |
| d-.gamma.-glutamyl-l-tryptophan |
| (2r)-2-amino-5-[[(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoic acid |
| golotimod [usan] |
| golotimod [who-dd] |
| golotimod [inn] |
| DB05475 |
| SCHEMBL727944 |
| DTXSID10177474 |
| CHEBI:177459 |
| mfcd28137704 |
| CATMPQFFVNKDEY-YPMHNXCESA-N |
| h-d-glu(l-trp-oh)-oh |
| AKOS030573318 |
| BCP24651 |
| h-d-glu(l-trp-oh)-oh;scv 07;gamma-d-glu-l-trp;scv-07;scv07 |
| (r)-2-amino-5-(((s)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid |
| Q27095684 |
| golotimod (scv-07) |
| HY-14743 |
| CS-0003532 |
| nsc-755401 |
| nsc755401 |
| h-gamma-d-glu-trp-oh; bestim |
| MS-25023 |
Drug Classes (1)
| Class | Description |
|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |